Aditxt, Inc. Selling and Marketing Expense
Aditxt, Inc. (ADTX) reported Selling and Marketing Expense of $402.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-05-20
- Aditxt, Inc. selling and marketing expense for the quarter ending 2025-12-31 was -$4.00K, a 103.87% decline year-over-year.
- Aditxt, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $6.04K, a 79.87% decline year-over-year.
- Aditxt, Inc. selling and marketing expense for the quarter ending 2025-06-30 was $349.03K, a 1341.20% increase year-over-year.
- Aditxt, Inc. selling and marketing expense for the quarter ending 2025-03-31 was $50.92K, a 25.69% increase year-over-year.
- Aditxt, Inc. selling and marketing expense for fiscal 2025 was $402.00K, a 103.17% increase from fiscal 2024.
- Aditxt, Inc. selling and marketing expense for fiscal 2024 was $197.86K, a 26.52% decline from fiscal 2023.
- Aditxt, Inc. selling and marketing expense for fiscal 2023 was $269.28K, a 85.44% decline from fiscal 2022.
- Aditxt, Inc. selling and marketing expense for fiscal 2022 was $1.85M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.04K derived: sum of 2 quarters · filed 2026-03-31 | $351.08K derived: sum of 3 quarters · filed 2026-03-31 | $402.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $6.04K 10-Q · filed 2025-11-18 | $355.07K derived: sum of 2 quarters · filed 2025-11-18 | $405.99K 10-Q · filed 2025-11-18 | $509.12K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $349.03K 10-Q · filed 2025-08-14 | $399.95K 10-Q · filed 2025-08-14 | $503.08K derived: sum of 3 quarters · filed 2026-05-20 | $533.08K derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $50.92K 10-Q · filed 2026-05-20 | $154.05K derived: sum of 2 quarters · filed 2026-05-20 | $184.05K derived: sum of 3 quarters · filed 2026-05-20 | $208.27K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $103.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $133.13K derived: sum of 2 quarters · filed 2026-03-31 | $157.35K derived: sum of 3 quarters · filed 2026-03-31 | $197.86K 10-K · filed 2026-03-31 |
| 2024-09-30 | $30.00K 10-Q · filed 2025-11-18 | $54.22K derived: sum of 2 quarters · filed 2025-11-18 | $94.73K 10-Q · filed 2025-11-18 | $140.45K derived: sum of 4 quarters · filed 2025-11-18 |
| 2024-06-30 | $24.22K 10-Q · filed 2025-08-14 | $64.73K 10-Q · filed 2025-08-14 | $110.45K derived: sum of 3 quarters · filed 2025-08-14 | $154.64K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $40.51K 10-Q · filed 2025-05-15 | $86.23K derived: sum of 2 quarters · filed 2025-05-15 | $130.42K derived: sum of 3 quarters · filed 2025-05-15 | $244.18K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $45.72K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $89.91K derived: sum of 2 quarters · filed 2025-03-31 | $203.67K derived: sum of 3 quarters · filed 2025-03-31 | $269.28K 10-K · filed 2025-03-31 |
| 2023-09-30 | $44.19K 10-Q · filed 2024-11-18 | $157.94K derived: sum of 2 quarters · filed 2024-11-18 | $223.56K 10-Q · filed 2024-11-18 | $1.16M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | $113.76K 10-Q · filed 2024-08-19 | $179.38K 10-Q · filed 2024-08-19 | $1.12M derived: sum of 3 quarters · filed 2024-08-19 | $1.11M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $65.62K 10-Q · filed 2024-05-20 | $1.00M derived: sum of 2 quarters · filed 2024-05-20 | $994.54K derived: sum of 3 quarters · filed 2024-05-20 | $1.83M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $937.47K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $928.92K derived: sum of 2 quarters · filed 2024-04-16 | $1.76M derived: sum of 3 quarters · filed 2024-04-16 | $1.85M 10-K · filed 2024-04-16 |
| 2022-09-30 | -$8.55K 10-Q · filed 2023-11-14 | $825.39K derived: sum of 2 quarters · filed 2023-11-14 | $911.99K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $833.94K 10-Q · filed 2023-08-14 | $920.54K 10-Q · filed 2023-08-14 | ||
| 2021-09-30 | $150.06K 10-Q · filed 2022-11-14 | $252.56K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |